---
id: 056
title: Daptomycin CPK Elevation and Myopathy
category: antimicrobials
subcategory: daptomycin
tags: [daptomycin, CPK, myopathy, rhabdomyolysis, statins, monitoring]
difficulty: medium
---

## Question

What is the risk of **CPK elevation and myopathy** with daptomycin, and how should it be monitored? Use the **"CHECK CPK Weekly"** mnemonic.

## Answer

### **"CHECK CPK Weekly" Mnemonic:**

**CHECK CPK:**
- **C**PK elevation common (up to 12%)
- **H**igher risk with statins (OR 2.60)
- **E**levated >5× ULN + symptoms → stop
- **C**reatine kinase monitoring required
- **K**eep monitoring weekly

**Weekly:**
- **W**eekly CPK checks mandatory
- **E**specially if renal impairment
- **E**levated >10× ULN asymptomatic → stop
- **K**ill drug if rhabdomyolysis
- **L**ook for muscle pain/weakness
- **Y**ield better outcomes with monitoring

### **CPK Elevation Incidence:**

| CPK Level | Frequency | Action |
|-----------|-----------|--------|
| **Any elevation** | 11.8% | Monitor closely |
| **>500 U/L** | 11.8% | Median onset: 13 days |
| **>1000 U/L (>5× ULN)** | 2-3% with symptoms | **Discontinue** |
| **>2000 U/L (>10× ULN)** | <1% asymptomatic | **Discontinue** |

### **Risk Factors for Daptomycin-Associated Myopathy:**

| Risk Factor | Odds Ratio | Notes |
|-------------|------------|-------|
| **Statin coadministration** | **2.60** (myopathy)<br>**4.67** (rhabdo) | HIGHEST RISK |
| **Renal impairment** (CrCl <30) | 2-3× | Reduced clearance |
| **High-dose daptomycin** (>6 mg/kg) | Variable | More monitoring needed |
| **Duration >14 days** | Increased | Risk cumulative |
| **Concurrent nephrotoxins** | Variable | NSAIDs, vancomycin |

### **Clinical Monitoring Protocol:**

**Baseline (Before Starting Daptomycin):**
- CPK level
- Renal function (CrCl)
- Review medication list (statins, fibrates)

**During Therapy:**

| Frequency | When | Action |
|-----------|------|--------|
| **Weekly CPK** | All patients | Standard monitoring |
| **More frequent** (2-3×/week) | Renal impairment, statins, high-dose | Enhanced monitoring |
| **Symptoms develop** | Myalgia, weakness | Check CPK immediately |

**Discontinuation Criteria:**

| Scenario | CPK Level | Symptoms | Action |
|----------|-----------|----------|--------|
| **Symptomatic myopathy** | **>5× ULN (>1000 U/L)** | Muscle pain, weakness | **Stop daptomycin** |
| **Asymptomatic** | **>10× ULN (>2000 U/L)** | None | **Stop daptomycin** |
| **Rhabdomyolysis** | Very high | Myoglobinuria, AKI | **Stop immediately** |

## Key Points

### **Clinical Presentation of Daptomycin Myopathy:**

**Symptoms:**
- Muscle pain, tenderness
- Proximal muscle weakness
- Fatigue
- Dark urine (myoglobinuria if severe)

**Lab Findings:**
- ↑ CPK (often markedly elevated)
- ↑ Creatinine (if rhabdomyolysis)
- Myoglobinuria (severe cases)

**Timing:** Median onset ~13 days (range 2-50 days)

### **Management of Elevated CPK:**

**CPK 1-5× ULN:**
- Continue daptomycin if asymptomatic
- Increase monitoring frequency (2-3×/week)
- Counsel patient on symptoms

**CPK >5× ULN with symptoms OR >10× ULN asymptomatic:**
- **Discontinue daptomycin immediately**
- Hold statins if coadministered
- Monitor CPK until normalized
- Check renal function (risk of AKI)
- Supportive care (hydration)

**Rhabdomyolysis (CPK >>10× ULN + myoglobinuria + AKI):**
- Stop daptomycin immediately
- Aggressive IV hydration
- Monitor for compartment syndrome
- Dialysis if severe AKI

### **Statin Coadministration:**

**Evidence:**
- Statins independently associated with myopathy (OR 2.60)
- Rhabdomyolysis risk even higher (OR 4.67)

**Recommendations:**
- **Consider holding statin** during daptomycin therapy (if short-term)
- If statin necessary: Increase CPK monitoring to 2-3×/week
- Use lowest effective daptomycin dose
- Patient counseling on muscle symptoms

### **Dose Adjustment in Renal Impairment:**

| CrCl | Dose | Frequency |
|------|------|-----------|
| **≥30 mL/min** | Standard (4-6 mg/kg) | Daily |
| **<30 mL/min** | Same dose | **Every 48 hours** |
| **HD/CAPD** | Same dose | **After dialysis** (q48h) |

**Rationale:** Daptomycin accumulates in renal impairment → ↑ myopathy risk

### **Clinical Pearls:**
- **Weekly CPK monitoring is MANDATORY** (not optional)
- **Statins + daptomycin = HIGH RISK** combination
- **CPK elevation is REVERSIBLE** after discontinuation
- Median time to CPK normalization: 7-14 days
- **Renal impairment** significantly increases risk
- Higher doses (8-10 mg/kg) may require more frequent monitoring

## Sources

- [PMC3727605: Daptomycin and CPK Elevation]
- [PMC8651170: Risk Factors for Daptomycin CPK Elevation]
- [PMC6186852: Statin Coadministration and Daptomycin Myopathy]
- [StatPearls NBK470407: Daptomycin]

## Media

N/A
